J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yasui-Furukori, N.
Right arrow Articles by Tateishi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yasui-Furukori, N.
Right arrow Articles by Tateishi, T.

HERBAL MEDICINE

The Effects of Ginkgo biloba Extracts on the Pharmacokinetics and Pharmacodynamics of Donepezil

Norio Yasui-Furukori, MD, PhD, Hanako Furukori, MD, PhD, Ayako Kaneda, BS, Sunao Kaneko, MD, PhD and Tomonori Tateishi, MD, PhD

From the Department of Clinical Pharmacology (Dr. Yasui-Furukori, Dr. Tateishi) and Neuropsychiatry (Dr. Yasui-Furukori, Dr. Furukori, A. Kaneda, Dr. Kaneko), Hirosaki University School of Medicine, Hirosaki, Japan, and the Department of Psychiatry, Koroishi-Akebono Hospital, Kuroishi, Japan (Dr. Furukori, A. Kaneda).

The effects of ginkgo supplementation on the steady-state plasma concentration of donepezil and the activity of cholinesterase in red blood cells and cognitive function were examined. Fourteen inpatients with Alzheimer's disease received donepezil 5 mg/day, supplemented with extracts of Ginkgo biloba 90 mg/day for 30 days. Blood samples were collected before and during ginkgo supplementation and 30 days after its discontinuation, together with an assessment of cognitive function. Plasma drug concentration was measured using high-performance liquid chromatography (HPLC), and cholinesterase in red blood cells was measured using Ellman methods. Cognitive function was evaluated using the Mini-Mental Scale Examination (MMSE). Plasma concentration of donepezil during ginkgo supplementation (mean ± SD [95% confidence interval]; 24.4 ± 12.6 ng/mL [17.1-31.7 ng/mL]) was not significantly different from that before ginkgo supplementation (22.7 ± 10.3 ng/mL [16.8-28.7 ng/mL]) or that 4 weeks after its discontinuation (25.0 ± 12.9 ng/mL [17.6-32.4 ng/mL]). There was no significant difference between cholinesterase in red blood cells before ginkgo supplementation (1.75 ± 0.21 U [1.63-1.87 U]), during ginkgo supplementation (1.91 ± 0.27 U [1.76-2.07 U]), and 4 weeks after its discontinuation (1.83 ± 0.29 U [1.66-2.00 U]). Ginkgo supplementation did not alter MMSE scores throughout the study. The present study shows that ginkgo supplementation does not have major impact on the pharmacokinetics and pharmacodynamics of donepezil.

Key Words: Donepezil • Ginkgo biloba • pharmacokinetics • pharmacodynamics • drug-herb interaction • Alzheimer's disease

Address for reprints: Norio Yasui-Furukori, MD, PhD, Department of Clinical Pharmacology, Hirosaki University, School of Medicine, Hirosaki 036-8562, Japan.




This article has been cited by other articles:


Home page
 JCOHome page
A. Sparreboom, M. C. Cox, M. R. Acharya, and W. D. Figg
Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
J. Clin. Oncol., June 15, 2004; 22(12): 2489 - 2503.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Clinical Pharmacology